The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Maintenance Dosing Period to Evaluate the Efficacy and Safety of Secukinumab in Patients With Ichthyoses
Sponsor: Icahn School of Medicine at Mount Sinai
A PHASE2 clinical study on Autosomal Recessive Congenital Ichthyosis and Congenital Ichthyosiform Erythroderma, this trial is completed. The trial is conducted by Icahn School of Medicine at Mount Sinai and has accumulated 13 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Jun 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Icahn School of Medicine at Mount Sinai
- Northwestern University
For direct contact, visit the study record on ClinicalTrials.gov .